Business & Finance
News
1/9/2007
09:58 AM
Connect Directly
RSS
E-Mail
50%
50%

EFF Says First Amendment Protects Links To Leaked Corporate Documents

The Electronic Frontier Foundation claims that a writer has a right to link from a public wiki to electronic copies of Eli Lilly documents showing side effects of a drug.

An advocacy group claims the First Amendment allows citizen journalists to link from public Web pages to electronic copies of damaging internal documents.

The Electronic Frontier Foundation claims that an anonymous writer has a right to link from a public wiki to electronic copies of Eli Lilly documents showing side effects of Zyprexa, a drug used to treat schizophrenia and bipolar disorder. Federal District Court Judge Jack Weinstein ordered Web publishers to stop publishing the material and scheduled another court appearance in San Francisco for next week.

"Preventing a citizen-journalist from posting links to important health information on a public wiki violates the First Amendment," EFF Senior Staff Attorney Fred von Lohmann said in a prepared statement. "Eli Lilly's efforts to censor these documents off the Internet are particularly outrageous in light of the information reported by The New York Times, which suggests that doctors and patients who use Zyprexa need to know the information contained in those documents."

The EFF said media reports showed that the leaked Eli Lilly documents, from a liability lawsuit, contained evidence that the company downplayed the drug's side effects, including weight gain, high blood sugar, and diabetes, while marketing the drug for uses the Food and Drug Administration didn't approve.

The pharmaceutical company issued a statement to refute the article published by The New York Times, saying that the death of a patient profiled in the newspaper could not be attributed to any single factor, including medication.

"Millions of patients around the world have benefited from Zyprexa and Lilly is concerned that this tragic story about a single patient could unnecessarily frighten people with schizophrenia and bipolar disorder and cause them to discontinue their medication without first consulting a physician," the company stated Thursday, the same day it also announced a settlement in a Zyprexa liability lawsuit.

In all, Eli Lilly has agreed to pay up to $1.2 billion to settle claims relating to the drug. The company maintained in its prepared statement that the patient who died had a complicated medical history, as do many patients with schizophrenia. It pointed out that the FDA has approved the drug and said that patient safety is Eli Lilly's first priority.

EFF claims that several citizen journalists contributed to an in-depth analysis on the wiki, which explained that the company deliberately created a marketing campaign to downplay the risk of diabetes in patients taking Zyprexa.

Comment  | 
Print  | 
More Insights
The Business of Going Digital
The Business of Going Digital
Digital business isn't about changing code; it's about changing what legacy sales, distribution, customer service, and product groups do in the new digital age. It's about bringing big data analytics, mobile, social, marketing automation, cloud computing, and the app economy together to launch new products and services. We're seeing new titles in this digital revolution, new responsibilities, new business models, and major shifts in technology spending.
Register for InformationWeek Newsletters
White Papers
Current Issue
InformationWeek Tech Digest - August 27, 2014
Who wins in cloud price wars? Short answer: not IT. Enterprises don't want bare-bones IaaS. Providers must focus on support, not undercutting rivals.
Flash Poll
Video
Slideshows
Twitter Feed
InformationWeek Radio
Archived InformationWeek Radio
Howard Marks talks about steps to take in choosing the right cloud storage solutions for your IT problems
Sponsored Live Streaming Video
Everything You've Been Told About Mobility Is Wrong
Attend this video symposium with Sean Wisdom, Global Director of Mobility Solutions, and learn about how you can harness powerful new products to mobilize your business potential.